Development of a high throughput cell-based assay for soluble epoxide hydrolase using bacmam technology

Molecular Biotechnology

Volumn 45, Issue 3, 2010, Pages 207-217

  Xie, Wensheng ^a   Tang, Xiaoyan ^a   Lu, Quinn ^a   Ames, Robert S ^a   Ratcliffe, Steven J ^b   Li, Hu ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

BacMam technology; Cell based assay; Fluorescence polarization (FP); High throughput; Soluble epoxide hydrolase (sEH)

Indexed keywords

CELL CULTURE; CELLS; CYTOLOGY; DIAGNOSIS; FLUORESCENCE; HYDROLASES; POLARIZATION;

BACMAM TECHNOLOGY; CELL-BASED ASSAYS; EPOXIDE HYDROLASES; FLUORESCENCE POLARIZATION; HIGH THROUGHPUT;

THROUGHPUT;

14,15 DIHYDROXYEICOSATRIENOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; EPOXIDE HYDROLASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOTECHNOLOGY; CELL BASED GENE THERAPY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE POLARIZATION; HUMAN; HUMAN CELL; NONHUMAN;

ORYCTOLAGUS CUNICULUS;

EID: 77954958363     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12033-010-9271-8     Document Type: Article

References (52)

1. Campbell, W. B., Brady, M. T., Rosolowsky, L. J., & Falck, J. R. (1991). Metabolism of arachidonic acid by rat adrenal glomerulosa cells: Synthesis of hydroxyeicosatetraenoic acids and epoxyeicosatrienoic acids. Endocrinology, 128, 2183-2194.
2. Spector, A. A. (2009). Arachidonic acid cytochrome P450 epoxygenase pathway. Journal of Lipid Research, 50(Suppl), S52-S56.
3. Spector, A. A., & Norris, A. W. (2007). Action of epoxyeicosatrienoic acids on cellular function. American Journal of Physiology Cell Physiology, 292, C996-C1012.
4. Fisslthaler, B., Popp, R., Kiss, L., Potente, M., Harder, D. R., Fleming, I., et al. (1999). Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature, 401, 493-497. (Pubitemid 29470209)
5. Gauthier, K. M., Yang, W., Gross, G. J., & Campbell, W. B. (2007). Roles of epoxyeicosatrienoic acids in vascular regulation and cardiac preconditioning. Journal of Cardiovascular Pharmacology, 50, 601-608.
6. Larsen, B. T., Gutterman, D. D., & Hatoum, O. A. (2006). Emerging role of epoxyeicosatrienoic acids in coronary vascular function. European Journal of Clinical Investigation, 36, 293-300.
7. Fleming, I. (2007). Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins & Other Lipid Mediators, 82, 60-67.
8. Batchu, S. N., Law, E., Brocks, D. R., Falck, J. R., & Seubert, J. M. (2009). Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. Journal of Molecular and Cellular Cardiology, 46, 67-74.
9. Proctor, K. G., Falck, J. R., & Capdevila, J. (1987). Intestinal vasodilation by epoxyeicosatrienoic acids: Arachidonic acid metabolites produced by a cytochrome P450 monooxygenase. Circulation Research, 60, 50-59.
10. Weintraub, N. L., Fang, X., Kaduce, T. L., VanRollins, M., Chatterjee, P., & Spector, A. A. (1997). Potentiation of endothelium- dependent relaxation by epoxyeicosatrienoic acids. Circulation Research, 81, 258-267.
11. Yang, W., Holmes, B. B., Gopal, V. R., Kishore, R. V., Sangras, B., Yi, X. Y., et al. (2007). Characterization of 14, 15-epoxyeicosatrienoyl- sulfonamides as 14, 15-epoxyeicosatrienoic acid agonists: Use for studies of metabolism and ligand binding. The Journal of pharmacology and experimental therapeutics, 321, 1023-1031.
12. Lu, T., Ye, D., Wang, X., Seubert, J. M., Graves, J. P., Bradbury, J. A., et al. (2006). Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms. The Journal of Physiology, 575, 627-644.
13. Zou, A. P., Fleming, J. T., Falck, J. R., Jacobs, E. R., Gebremedhin, D., Harder, D. R., et al. (1996). Stereospecific effects of epoxyeicosatrienoic acids on renal vascular tone and K(?)- channel activity. The American Journal of Physiology, 270, F822-F832.
14. Li, P. L., & Campbell, W. B. (1997). Epoxyeicosatrienoic acids activate K? channels in coronary smooth muscle through a guanine nucleotide binding protein. Circulation Research, 80, 877-884.
15. Yang, W., Tuniki, V. R., Anjaiah, S., Falck, J. R., Hillard, C. J., & Campbell, W. B. (2008). Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-125i-14,15- epoxyeicosa-8(Z)-enoic acid. The Journal of Pharmacology and Experimental Therapeutics, 324, 1019-1027.
16. Shi, Y., Liu, X., Gebremedhin, D., Falck, J. R., Harder, D. R., & Koehler, R. C. (2008). Interaction of mechanisms involving epoxyeicosatrienoic acids, adenosine receptors, and metabotropic glutamate receptors in neurovascular coupling in rat whisker barrel cortex. Journal of Cerebral Blood Flow and Metabolism, 28, 111-125.
17. Behm, D. J., Ogbonna, A., Wu, C., Burns-Kurtis, C. L., & Douglas, S. A. (2009). Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: Identification of a novel mechanism of vasodilation. The Journal of Pharmacology and Experimental Therapeutics, 328, 231-239.
18. Chen, J. K., Capdevila, J., & Harris, R. C. (2001). Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Molecular and Cellular Biology, 21, 6322-6331.
19. Yang, S., Lin, L., Chen, J. X., Lee, C. R., Seubert, J. M., Wang, Y., et al. (2007). Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor- alpha via MAPK and PI3K/Akt signaling pathways. American Journal of Physiology, 293, H142-H151.
20. Beetham, J. K., Tian, T., & Hammock, B. D. (1993). cDNA cloning and expression of a soluble epoxide hydrolase from human liver. Archives of Biochemistry and Biophysics, 305, 197-201.
21. Newman, J. W., Morisseau, C., & Hammock, B. D. (2005). Epoxide hydrolases: Their roles and interactions with lipid metabolism. Progress in Lipid Research, 44, 1-51.
22. Pacifici, G. M., Temellini, A., Giuliani, L., Rane, A., Thomas, H., & Oesch, F. (1988). Cytosolic epoxide hydrolase in humans: Development and tissue distribution. Archives of Toxicology, 62, 254-257. (Pubitemid 18266672)
23. Enayetallah, A. E., French, R. A., Thibodeau, M. S., & Grant, D. F. (2004). Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. Journal of Histochemistry and Cytochemistry, 52, 447-454.
24. Chiamvimonvat, N., Ho, C. M., Tsai, H. J., & Hammock, B. D. (2007). The soluble epoxide hydrolase as a pharmaceutical target for hypertension. Journal of Cardiovascular Pharmacology, 50, 225-237.
25. Inceoglu, B., Schmelzer, K. R., Morisseau, C., Jinks, S. L., & Hammock, B. D. (2007). Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins & Other Lipid Mediators, 82, 42-49.
26. Zhang, W., Koerner, I. P., Noppens, R., Grafe, M., Tsai, H. J., Morisseau, C., et al. (2007). Soluble epoxide hydrolase: A novel therapeutic target in stroke. Journal of Cerebral Blood Flow and Metabolism, 27, 1931-1940.
27. Sinal, C. J., Miyata, M., Tohkin, M., Nagata, K., Bend, J. R., & Gonzalez, F. J. (2000). Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. The Journal of Biological Chemistry, 275, 40504-40510.
28. Zhang, W., Otsuka, T., Sugo, N., Ardeshiri, A., Alhadid, Y. K., Iliff, J. J., et al. (2008). Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. Stroke; A Journal of Cerebral Circulation, 39, 2073-2078.
29. Corenblum, M. J., Wise, V. E., Georgi, K., Hammock, B. D., Doris, P. A., & Fornage, M. (2008). Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat. Hypertension, 51, 567-573.
30. Fornage, M., Hinojos, C. A., Nurowska, B. W., Boerwinkle, E., Hammock, B. D., Morisseau, C. H., et al. (2002). Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension, 40, 485-490.
31. Morisseau, C., Goodrow, M. H., Dowdy, D., Zheng, J., Greene, J. F., Sanborn, J. R., et al. (1999). Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proceedings of the National Academy of Sciences of the United States of America, 96, 8849-8854.
32. Morisseau, C., Goodrow, M. H., Newman, J. W., Wheelock, C. E., Dowdy, D. L., & Hammock, B. D. (2002). Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochemical Pharmacology, 63, 1599-1608.
33. McElroy, N. R., Jurs, P. C., Morisseau, C., & Hammock, B. D. (2003). QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds. Journal of Medicinal Chemistry, 46, 1066-1080.
34. Li, J., Carroll, M. A., Chander, P. N., Falck, J. R., Sangras, B., & Stier, C. T. (2008). Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. Frontiers in Bioscience, 13, 3480-3487.
35. Olearczyk, J. J., Quigley, J. E., Mitchell, B. C., Yamamoto, T., Kim, I. H., Newman, J. W., et al. (2009). Administration of a substituted adamantly-urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clinical Science (Lond), 116, 61-70.
36. Imig, J. D., Zhao, X., Capdevila, J. H., Morisseau, C., & Hammock, B. D. (2002). Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension, 39, 690-694.
37. Zhao, X., Yamamoto, T., Newman, J. W., Kim, I. H., Watanabe, T., Hammock, B. D., et al. (2004). Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. Journal of the American Society of Nephrology, 15, 1244-1253.
38. Smith, K. R., Pinkerton, K. E., Watanabe, T., Pedersen, T. L., Ma, S. J., & Hammock, B. D. (2005). Attenuation of tobacco smokeinduced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 102, 2186-2191.
39. Ghosh, S., Chiang, P. C., Wahlstrom, J. L., Fujiwara, H., Selbo, J. G., & Roberds, S. L. (2008). Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. Basic & Clinical Pharmacology & Toxicology, 102, 453-458.
40. Nithipatikom, K., Falck, J. R., Bhatt, R. K., Hanke, C. J., & Campbell, W. B. (1997). Determination of 14,15-epoxyeicosatrienoic acid and 14,15-dihydroxyeicosatrienoic acid by fluoroimmunoassay. Analytical Biochemistry, 246, 253-259.
41. Wolf, N. M., Morisseau, C., Jones, P. D., Hock, B., & Hammock, B. D. (2006). Development of a high-throughput screen for soluble epoxide hydrolase inhibition. Analytical Biochemistry, 355, 71-80.
42. Jones, P. D., Wolf, N. M., Morisseau, C., Whetstone, P., Hock, B., & Hammock, B. D. (2005). Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. Analytical Biochemistry, 343, 66-75.
43. Owicki, J. C. (2000). Fluorescence polarization and anisotropy in high throughput screening: Perspectives and primer. Journal of Biomolecular Screening, 5, 297-306.
44. Luckow, V. A., Lee, S. C., Barry, G. F., & Olins, P. O. (1993). Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in Escherichia coli. Journal of Virology, 67, 4566-4579.
45. Fornwald, J. A., Lu, Q., Wang, D., & Ames, R. S. (2007). Gene expression in mammalian cells using BacMam, a modified baculovirus system. Methods in Molecular Biology, 388, 95-114.
46. Kost, T. A., Condreay, J. P., Ames, R. S., Rees, S., & Romanos, M. A. (2007). Implementation of BacMam virus gene delivery technology in a drug discovery setting. Drug discovery today, 12, 396-403.
47. Ames, R. S., Kost, T. A., & Condreay, J. P. (2007). BacMam technology and its application to drug discovery. Expert Opinion on Drug Discovery, 2, 1669-1681.
48. Condreay, J. P., Ames, R. S., Hassan, N. J., Kost, T. A., Merrihew, R. V., Mossakowska, D. E., et al. (2006). Baculoviruses and mammalian cell-based assays for drug screening. Advances in Virus Research, 68, 255-286.
49. Yang, J., Copeland, R. A., & Lai, Z. (2009). Defining balanced conditions for inhibitor screening assays that target bisubstrate enzymes. Journal of Biomolecular Screening, 14, 111-120.
50. Macarron, R., & Hertzberg, R. P. (2002). Design and implementation of high throughput screening assays. Methods in Molecular Biology, 190, 1-29.
51. Zhang, J. H., Chung, T. D., & Oldenburg, K. R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. Journal of Biomolecular Screening, 4, 67-73.
52. Kerr, B. M., Rettie, A. E., Eddy, A. C., Loiseau, P., Guyot, M., Wilensky, A. J., et al. (1989). Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: In vitro/in vivo correlation. Clinical Pharmacology and Therapeutics, 46, 82-93.